Literature DB >> 8549169

Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas.

L Johansson1, C J Lindén.   

Abstract

BACKGROUND: The prognosis of patients with pleural mesothelioma is more dependent on "pretreatment factors" than on the effect of therapeutic interventions. Histopathologic subtype is one of several important prognostic factors in pleural mesothelioma, and several studies indicate that the epithelial subtype of pleural mesotheliomas has a more favorable prognosis than the sarcomatoid. In this study, we retrospectively evaluated qualitative and quantitative aspects of the tissue specimens used for histopathologic diagnosis in 85 patients with pleural mesothelioma.
MATERIALS AND METHODS: The prognostic roles of two different histopathologic classification systems were evaluated in 85 consecutive cases of pleural mesotheliomas. Efficiency of different diagnostic procedures, influence of the size of the biopsy specimens on the histopathologic diagnosis, and immunohistochemical profiles for histopathologic subtypes of mesotheliomas were also evaluated.
RESULTS: Patients with pure epithelial mesotheliomas (n = 35), and especially those with the tubulopapillary subtype (n = 18) of epithelial mesotheliomas, survived significantly longer than those with a sarcomatoid component (n = 50). With larger biopsy specimens (surgical biopsy, autopsy), more tumors were classified as biphasic (36/78 vs 9/44, p < 0.005). The sarcomatoid mesotheliomas comprised about 20% of the tumors regardless of type of biopsy. Staining intensity for cytokeratin CAM 5.2 was equal in all types of mesotheliomas, while intensity with cytokeratin AE1/AE3 decreased from the epithelial to the sarcomatoid mesotheliomas. Staining with vimentin was most intense among the sarcomatoid mesotheliomas, while with epithelial membrane antigen it was most intense among the epithelial mesotheliomas.
CONCLUSIONS: The quality of the biopsy specimens has considerable impact on the possibility to arrive at a correct histopathologic diagnosis. Based on our results, we suggest tubulopapillary mesotheliomas be regarded as "low-grade mesotheliomas" and other types, including the epithelioid type of epithelial mesotheliomas, as "high-grade mesotheliomas." This should be taken into account when designing clinical trials.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8549169     DOI: 10.1378/chest.109.1.109

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  13 in total

1.  Chromosomal alterations in early stages of malignant mesotheliomas.

Authors:  Frank Simon; Georg Johnen; Michael Krismann; Klaus-Michael Müller
Journal:  Virchows Arch       Date:  2005-10-19       Impact factor: 4.064

2.  Early-stage Clinical Characterization of Malignant Pleural Mesothelioma.

Authors:  Yoshiki Negi; Kozo Kuribayashi; Norihiko Funaguchi; Hiroshi Doi; Koji Mikami; Toshiyuki Minami; Teruhisa Takuwa; Takashi Yokoi; Seiki Hasegawa; Takashi Kijima
Journal:  In Vivo       Date:  2018 Sep-Oct       Impact factor: 2.155

3.  Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma.

Authors:  Lucian R Chirieac; Yin P Hung; Wai Chin Foo; Matthias D Hofer; Paul A VanderLaan; William G Richards; David J Sugarbaker; Raphael Bueno
Journal:  Cancer       Date:  2019-08-07       Impact factor: 6.860

4.  Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases.

Authors:  Jinru Shia; Jing Qin; Robert A Erlandson; Roy King; Peter Illei; Jennifer Nobrega; Davis Yao; David S Klimstra
Journal:  Virchows Arch       Date:  2005-07-14       Impact factor: 4.064

5.  Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma.

Authors:  A Baldi; D Santini; F Vasaturo; M Santini; G Vicidomini; M Pia Di Marino; V Esposito; A M Groeger; G Liuzzi; B Vincenzi; G Tonini; M Piccoli; F Baldi; S Scarpa
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

6.  Differential expression of Ki-67 and sex steroid hormone receptors between genders in peritoneal mesothelioma.

Authors:  Terence C Chua; Peng Yao; Javed Akther; Lawrence Young; Shisan Bao; Ushma Samaraweera; Tristan D Yan; David L Morris
Journal:  Pathol Oncol Res       Date:  2009-04-29       Impact factor: 3.201

Review 7.  Peritoneal mesothelioma.

Authors:  R N Taub; M L Keohan; J C Chabot; K S Fountain; M Plitsas
Journal:  Curr Treat Options Oncol       Date:  2000-10

8.  Pleural mesothelioma: an institutional experience of 66 cases.

Authors:  Soomin Ahn; In Ho Choi; Joungho Han; Jhingook Kim; Myung-Ju Ahn
Journal:  Korean J Pathol       Date:  2014-04-28

9.  Malignant peritoneal mesothelioma: correlation between CT imaging features and histologic subtypes.

Authors:  Isha D Atre; Gaurav V Watane; Mukesh G Harisinghani
Journal:  Abdom Radiol (NY)       Date:  2021-08-03

10.  The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.

Authors:  Ymera Pignochino; Carmine Dell'Aglio; Simona Inghilleri; Michele Zorzetto; Marco Basiricò; Federica Capozzi; Marta Canta; Davide Piloni; Francesca Cemmi; Dario Sangiolo; Loretta Gammaitoni; Marco Soster; Serena Marchiò; Ernesto Pozzi; Patrizia Morbini; Maurizio Luisetti; Massimo Aglietta; Giovanni Grignani; Giulia M Stella
Journal:  BMC Cancer       Date:  2015-05-08       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.